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Pilocytic and pilomyxoid astrocytomas are some of the most 
common gliomas in children and young adults. These gliomas are 
indolent neoplasms with long overall survival probability. The 
genetic characteristics of these neoplasms are well known, and our 
deepened understanding of their associated molecular alterations has 
led to the development of novel treatment strategies and approaches. 
Currently, we can account for some of the unusual behavior, such as 
oncogene-induced senescence, associated spontaneous regression, 
anaplastic transformation, and cerebrospinal dissemination, of these 
gliomas. Nevertheless, enigmatic issues continue to surround these 
chronic tumors. Here, we review the classical and uncommon clinical 
pathological and genetic features of these indolent gliomas.
Keywords: Astrocytoma, glioma, mitogen-activated protein kinase 
pathway, oncogene-induced senescence, pilocytic, pilomyxoid 
Pilocytic astrocytomas (PAs) are the most common primary gliomas 
in children and adolescents (0-19 years of age). A recent CBTRUS 
report stated that PAs account for approximately 15.6% of brain 
tumors (1). In the United States, the annual incidence of PAs is 
approximately 0.35-0.37 per 100.000 persons. This incidence peaks 
among children aged 0-9 years and decreases with advancing age 
(1).
Bailey and Cushing (2) historically referred to PAs as 
“spongioblastoma unipolare”. Subsequently, Penfield and his 
colleagues from the Montreal Neurological Institute introduced the 
term “piloid (hair-like) astrocytes” to describe astrocytes with long 
parallel hair-like fibers that are found in areas of gliosis (3). The term 
“pilocytic astrocytoma” was later used by Russell and Bland (4) and 
was officially used in the 1979 WHO classification (5). The current 
WHO classification defines PA as a WHO grade I neoplasm (6).
PA often presents indolent behavior and has excellent prognosis 
with overall survival rates of more than 20 years. Given these 
characteristics, PA is considered as a “chronic disease”, a neoplasm 
that requires a tempered approach and long-term follow-up (7). 
However, except for the recently described PA variant, pilomyxoid 
astrocytoma (PMA), a small percentage of PAs exhibits aggressive 
behavior that may not be predictable upon histological examination 
(8).
Considerable information about PA, including its defining genetic 
aberrations, potential for spontaneous regression, unpredictable 
radiation response, and anaplastic transformation, has been 
gleaned over the past decade. In this review, we present our current 
understanding of the histopathologic, radiologic, and molecular 
aspects of PA and its variant, PMA. We also discuss critical issues, 
such as prognostically relevant parameters, that may provide insight 
into the biological behaviors of these gliomas.
Clinical Considerations
PA can occur anywhere within the neuraxis. In children, they 
usually arise in the posterior fossaand less commonly in the spinal 
or supratentorial regions. Among adults, the incidences of PA in 
infra- and supratentorial locations negligibly differ (9). PAs can 
arise in association with neurofibromatosis type 1 (NF1), wherein 
they most commonly manifest as “optic glioma,” a nonspecific 
term that implies the involvement of the optic nerve proper (10). 
Progression-free and overall survival probabilities are influenced by 
several factors, including the location of the tumor and the extent 
of resection, and may be modified by access to healthcare (11). 
Patients who undergo the gross total resection of their tumors have 
excellent prognosis (12), whereas those with deeply situated lesions 
and who receive subtotal resections may experience recurrence 
(13). Yet, even subtotally resected tumors may not progress over 
time. Overall, PAs are slow-growing indolent neoplasms with 10-
year survival rates that exceed 95% (9).
An interesting and widely reported feature of PA is its propensity to 
undergo spontaneous regression (14,15). This phenomenon can be 
observed after subtotal resection and in the absence of any adjuvant 
treatment. The biological mechanisms underlying tumor regression 
remain poorly elucidated. Moreover, the spontaneous regression of 
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PA cannot be accurately predicted. Oncogene-induced senescenc 
edriven by mitogen-activated protein kinase (MAPK) may play 
a major role in the tumor regression and long-term survival of 
patients with PA. 
The clinical presentation of PA directly reflects its location. 
Patients with posterior fossa tumors generally present with slowly 
progressive headaches, nausea, vomiting, or ataxia, as well as other 
signs and symptoms of cerebellar dysfunction. Cerebral tumors often 
present with focal signs peculiar to the location of the tumor. Tumors 
involving the hypothalamus and adjacent visual pathways can cause 
visual loss or field defects, as well as symptoms and signs related to 
hypothalamic-pituitary dysfunction, e.g. obesity, diabetes insipidus, 
ordiencephalic syndrome (16). Tumors involving the thalamus 
and basal ganglia can cause contralateral weakness. Seizures are 
exceptional even with cerebral tumors. Tumors of the optic nerve can 
cause visual loss and may induce proptosis. Spinal cord tumors can 
cause signs of cord compression. Infrequently, patients may present 
with acute neurological deficits due to intratumoral hemorrhage 
(17-19), which may present a diagnostic challenge because its rapid 
clinical course and complex appearance on magnetic resonance 
imaging (MRI) are suggestive of a high-grade neoplasm or a vascular 
malformation. Rarely, PA, particularly PMA, may present with 
evidence of dissemination or cerebrospinal fluid spread (8,20-23).
Radiologic Features
PA is typically a well-circumscribed, cystic mass with a contrast-
enhancing intramural nodule and little/no peritumoral edema or 
mass effect (Figure 1). Tumor calcification may be occasionally 
recognized on computed tomography or MRI. On MRI, the nodule 
is usually iso-or hypointense to gray matter on T1-weighted images 
and hyperintense on T2-weighted images. Some cases may exhibit 
the distortion of the fourth ventricle and associated hydrocephalus. 
The radiological designation of “exophytic” tumor in the brainstem 
is often associated with PA. However, this designation is often used 
too loosely to be of specific significance. Tumors of the optic nerve 
are typically solid without a cystic component, cause the expansion 
and distortion of the nerve, and may result in the “dotted i” 
appearance of the intraorbital optic nerve by causing the buckling 
of the nerve just proximal to the globe (Figure 1c). Hypothalamic 
tumors are mostly solid (Figure 1e). PMA typically occurs in the 
hypothalamus, particularly in young children. In the supratentorial 
region, PA scan arise adjacent to the third ventricle and show a 
typical cystic and solid appearance (Figure 1b) (24,25).
Similar to PA, PMAs are most commonly located in the 
hypothalamic/chiasmatic region, although they can occur in other 
locations in the neuraxis (26). However, in contrast to PA, they are 
predominantly solid and rarely have cystic components (27,28). 
Some hypothalamic/chiasmatic PMAs appear as solid, bulky 
masses (Figure 1f) and may extend into the temporal lobes (24). 
Almost all PMAs are well circumscribed and show little or no 
peritumoral edema (29). On MRI, they are typically hypointense 
on T1-weighted images and hyperintense on T2-weighted images 
(6,28). They show homogeneous or heterogeneous contrast 
enhancement (28,29). Intratumoral hemorrhage has been reported 
4
Balkan Med J, Vol. 36, No. 1, 2019
Ding and Tihan. Pilocytic and Pilomyxoid Astrocytomas
FIG. 1. a-f. Radiologic features of pilocytic and pilomyxoid astrocytoma on magnetic resonance imaging. Pilocytic astrocytomas displaying typical circumscribed, cystic appearances with 
enhancing mural nodules in the (a) cerebellum and (b) supratentorial region. Expansion of the left optic nerve by a solid, enhancing pilocytic astrocytomas (c). T2-weighted and contrast-
enhanced images from an intramedullary pilocytic astrocytomas involving the spinal cord (d). Mainly solid, enhancing pilocytic astrocytomas with minimal cystic component involving 
the hypothalamic region (e). Lobulated, solid enhancing pilomyxoid astrocytoma involving the hypothalamic region (f). All figures are contrast-enhanced T1 weighted images, with the 
exception of the one-dimensional T2-weighted image showing a spinal cord tumor. 
in up to 25% of tumors in one series; this rate is higher than that 
reported for PAs (26). Radiologic evidence of cerebrospinal fluid 
dissemination tends to be more common in PMA than in PA (23).
Histological Features
Classically, PAs are noninfiltrating tumors that display low to 
moderate cellularity and a characteristic biphasic pattern with 
varying proportions of compact, bipolar cells with hair-like fibrillary 
processes. Most PAs harbor Rosenthal fibers within their compact 
or fibrillary areas. Although the presence of Rosenthal fibers in 
compact or fibrillary areas is a highly helpful feature in recognizing 
PA, it is not an absolute requirement for diagnosis. Another caveat 
with Rosenthal fibers is that their presence in the reactive glial 
tissues that surround other indolent tumors may mislead the 
observer to consider PA. Tumors, such as pineal parenchymal 
tumors, craniopharyngiomas, and hemangioblastomas, as well 
as ependymomas of the spinal cord, often incite reactive gliosis 
and Rosenthal fiber formation in the adjacent neuropil, sometimes 
leading to the misrecognition of the tumor as PA. 
A typical histological appearance of PA is that of loose areas with 
multipolar cells associated with microcysts. This pattern combined 
with focal myxoid (or mucinous) changes sometimes invokes the 
diagnosis of “microcystic astrocytoma,” an arcane term typically 
used for diffuse astrocytomas in the cerebrum. Eosinophilic 
granular bodies may also be present but are often fewer than 
Rosenthal fibers (Figure 2a-2d). Notably, the biphasic pattern is 
seen in only a proportion of cases and is thus not essential for 
diagnosis (30). Some tumors, especially those of the cerebellum, 
may show areas that resemble oligodendroglioma (Figure 2g), 
whereas others may show a polar spongioblastoma-like pattern 
that demonstrates a step-ladder formation characterized by nuclear 
palisades (Figure 2h) (30,31). Cytologically, the cells display 
uniform, bland nuclei, although some cells with hyperchromatic 
and pleomorphic nuclei unaccompanied by increased mitoses may 
be present. Degenerative atypia that feature pleomorphic nuclei and 
nuclear-cytoplasmic inclusions and enlarged cells with multiple 
nuclei arranged peripherally (Bernd W. Scheithauer’s “pennies 
on a plate” arrangement) may also be present (Figure 2e) (6). PAs 
are highly vascular tumors and can present a linear arrangement 
of glomeruloid vascular proliferation (Figure 2f) that outlines 
the cystic space, as well as thick-walled hyalinized vessels and 
glomeruloid type proliferative capillaries in a linear arrangement 
along the cyst wall (30). Hemorrhage and regressive angiomatous 
vascular changes may be sufficiently prominent to simulate 
vascular malformation. The presence of nonpalisading, infarct-like 
necrosis is rare but has not been associated with aggressive behavior 
(32). Rare mitotic figures may be present. Similar to numerous 
low-grade neoplasms, such as gangliogliomas or pleomorphic 
xanthoastrocytomas, PA can spread into the subarachnoid space 
and extend through Virchow-Robin spaces. In such cases, the 
tumor cells attain a spindled morphology and may appear different 
from those in the intraaxial component; nevertheless, this feature 
has not been associated with aggressiveness (6,30). 
PAs usually show a variable degree of infiltration into the adjacent 
brain parenchyma despite radiologic circumscription. Some rare 
examples of PAs within the cerebellum present a diffuse microscopic 
appearance (the “diffuse PAs” of Bernd W. Scheithauer) while 
retaining typical compact or microcystic patterns at least focally 
and show similar prognosis as tumors with classical histological 
features (33,34). These tumor cells can infiltrate the adjacent 
parenchyma over distances of a few millimeters to centimeters 
but generally do not aggressively overrun the neuropil (6). 
Limited or small biopsies from these regions may cause diagnostic 
difficulty and misdiagnoses, e.g. as oligodendroglioma or diffuse 
astrocytoma. 
Immunohistochemical features of PA are helpful in their 
recognition. One of the most practically useful stains is the 
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FIG. 2. a-h. Histologic features of pilocytic astrocytomas. Bipolar cells with hair-like cytoplasmic processes that are best visualized with cytologic smears (H&E, original magnification 
400×) (a). Classic biphasic appearance featuring alternating compact and loose areas associated with microcystic spaces (H&E, original magnification 100×) (b). Compact areas containing 
numerous Rosenthal fibers (H&E, original magnification 200×) (c). Eosinophilic granular bodies (H&E, original magnification 200×) (d). Enlarged multinucleated cells with a “pennies on 
a plate” arrangement (H&E, original magnification 200×) (e). Glomeruloid vascular proliferation (H&E, original magnification 200×) (f). Oligodendroglioma-like region (H&E, original 
magnification 200×) (g). Polar spongioblastoma-like pattern (H&E, original magnification 200×) (h). 
neurofilament protein that typically highlights the non-infiltrative 
or solid nature of the tumor. One exception to this is the so-called 
diffuse pattern and the limited biopsies from the periphery of the 
tumor, where the solid nature of the tumor may not be readily 
recognized. The tumors are often strongly and diffusely positive 
with GFAP, Vimentin, Olig-2 (Figure 3a-c) and S100 protein, as 
well as the transcription factor SOX-10 (6,11,35,36). Absence of 
GFAP, Olig-2 and S100 staining is unusual and should lead one to 
question the diagnosis of PA. Many PAs demonstrate diffuse, albeit 
weak staining with Synaptophysin but even focal strong positive 
staining can be encountered (Figure 3d). Another neural antibody, 
MAP-2, can also be positive (Figure 3e) and may be focally 
strong in PA, while the neuronal antibody Neu-N is typically 
negative (11,35). Ki67 proliferation index is low in most cases. 
P53 is staining is weak to absent, but even weak positive staining 
tumors do not harbor TP53 mutations. Immunostaining for BRAF 
V600E-mutant protein may be positive in a rare tumor with this 
mutation (Figure 3g), but more often the antibodies against this 
mutant protein are not helpful in the interpretation (6). Tumors 
with the typical molecular composition also stain diffusely and 
strongly with the p16 antibodies and tumors that stain entirely 
negatively with this antibody may suggest a more aggressive 
behavior (Figure 3h). Many PAs are also positive with the WT-1 
antibody. While often not of any practical utility, staining with 
SOX2, NSE and CD56 can be positive in PA. CD34 is typically 
negative in tumor cells and highlight vasculature, a feature that 
differentiates PA from glioneuronal tumors such as ganglioglioma. 
Where available, pERK staining often correlates with the presence 
of MAPK pathway activation often associated with the typical 
BRAF duplication (11).
The designation of anaplasia in PA and the characterization of 
anaplastic PA as a distinct variant or a different entity entirely remain 
highly controversial. Nevertheless, anaplastic features in some PAs 
have been well documented (“PA with anaplasia”) despite their 
rarity (6). Anaplastic features may be observed at first presentation 
or in recurrent tumors with or without adjuvant treatment. The vast 
majority of PAs show morphologic stability even upon recurrence 
with only exceptional tumors exhibiting progression to anaplastic 
histology (9,37). Anaplastic features have been seen in only 
1.7% of 2200 PA cases (38). The histologic features of anaplasia 
include hypercellularity, moderate to severe cytologic atypia, and 
brisk mitotic activity (>4 mitoses per 10 high-power fields) with 
or without necrosis (6,38). The anaplastic component may display 
fibrillary, small cell, or epithelioid morphology, as well as increased 
Ki-67 labeling index, but most often the labeling index shows areas 
with low values typical of PA. Strong p53 staining has been reported 
in rare anaplastic examples, but whether this staining corresponds 
to a TP53 mutation remains unclear (38).
A considerable proportion of tumors with anaplasia have occurred 
in the setting of prior radiation therapy (38,39) even though 
anaplastic transformation is not always associated with a history 
of prior irradiation (37,38,40). This transformation can also occur 
in patients with NF1 (38,41). PAs with anaplasia are associated 
with poor median overall survival and progression-free survival 
compared with those associated with typical PA but better survival 
than that associated with diffuse high-grade gliomas. Patients with 
survival beyond 5 or 10 years have been reported (9,42). Given 
that anaplastic PAs are not aggressive, most authors avoid using 
the term “glioblastoma ex PA” (6,38). Anaplastic examples of 
PAs have not received a WHO grade in the most recent WHO 
classification scheme (6).
Pilomyxoid Variant
PMA is the only recognized variant of PA. The term “pilomyxoid” 
was first introduced in 1999 (8) and was subsequently codified 
as a WHO Grade II tumor in the 2007 WHO (43). These tumors 
tend to occur in young patients and appear to show a less 
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FIG. 3. a-h. Immunohistochemical features of pilocytic astrocytomas. PAs typically show diffuse positive staining for GFAP (original magnification, 200×) (a), Olig-2 (original magnification, 
200×) (b), and Vimentin (original magnification, 200×) (c). Synaptophysin expression (original magnification, 200×) (d) and MAP-2 expression (original magnification, 200×) may be 
present (e). Neurofilament stain highlighting a limited infiltrative pattern at the periphery of the tumor (original magnification, 200×) (f). BRAFV600e mutant protein expression is seen in 
rare tumors with the mutation (original magnification, 200×) (g). Loss of p16 staining may portend poor prognosis (original magnification, 200×) (h).
favorable prognosis than PA because they exhibit local recurrence 
and cerebrospinal spread (8,22). The true incidence of PMA is 
unknown given that they are often overlooked and sometimes over 
diagnosed among PAs. An original study in 1999 identified 18 
patients from a large cohort of 1013 patients with PAs, giving a rate 
of approximately 1.7%. A single-institution study found that PMA 
accounts for approximately 10% of cases previously diagnosed as 
PA within a 13-year period (44). Given variations in diagnostic 
criteria, a strong possibility exists that some studies overestimate 
the prevalence of PMA among pilocytic neoplasms.
Histologically, PMAs display a marked myxoid matrix and 
monomorphous bipolar cells that often radiate from vessels in an 
angiocentric pattern (Figure 4). Typically, the tumors are compact 
and noninfiltrative but may display infiltration and trap normal brain 
elements similar to those displayed by PA. PMAs lack Rosenthal 
fibers and a biphasic pattern and exceptionally demonstrate rare 
eosinophilic granular bodies. Mitotic figures may be present and 
are often more easily recognized compared with those in typical 
PA. Akin to PA, vascular proliferation often occurs in the form of 
linear glomeruloid tufts associated with the cyst wall. Rarely, some 
PMAs demonstrate focal, nonpalisading necrosis (6,22).
Features supportive of PMA as a variant of PA include the younger 
ages of patients with PMA compared with those of patients of PA 
(22), examples of differentiation or “maturation” from pilomyxoid 
to pilocytic morphology in recurrent tumors (45-47), and tumors 
showing “intermediate” pilomyxoid features. The latter has been 
well recognized and may actually be as common as the pure PMA 
variant, and the biological behavior of these “hybrid” tumors 
are not entirely clear (47). Given that focal pilomyxoid changes 
in an otherwise typical PA have not been associated with poor 
prognosis, these neoplasms may not warrant the designation of 
PMA (6). Nevertheless, commenting on the presence and extent of 
pilomyxoid features may be prudent because their exact behavior 
remains unclear (47).
The grading designation of PMA was removed from the 2016 
WHO classification because these tumors have similar molecular/
genetic characteristics. This unfortunate assessment was based on 
the uncertain interpretation of the biological behavior of PMA. 
Regardless of the decision regarding the WHO classification 
scheme, substantial evidence—and probably more robust evidence 
than many other entities in the current classification with a 
designated grade—shows that PMA follows a more aggressive 
course than PA even when controlled for age and location (48). 
Based on the available data in the literature, substantial evidence 
favors the characterization of PMA as a more aggressive and 
higher grade variant of PA, as demonstrated in well-designed and 
well-characterized cohort studies (22).
The immunohistochemical staining features of PA are virtually 
identical to those of PMA (Figure 5). PMAs are also positive for 
GFAP, S100 protein, vimentin, Olig-2, and SOX10, and some 
cases express synaptophysin (6,36,47). Staining for neurofilament 
and chromogranin-A are typically negative, or the former can show 
focal or limited axonal staining (6). A range of Ki-67 labeling index 
has been reported, but it is generally low (8,46). The Ki-67 labeling 
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FIG. 4. a-c. Histological features of PMA. Monomorphous bipolar tumor cells in an expansive myxoid matrix (H&E, original magnification 200×) (a,b). Tumor cells arranged in a radiating 
angiocentric pattern around vessels (H&E, original magnification 400×) (c).
FIG. 5. a-c. Immunohistochemical features of pilomyxoid astrocytoma. Positive staining for GFAP (original magnification, 200×) (a) and Olig-2 (original magnification, 400×) (b). 
Neurofilament stains may highlight an infiltrative pattern at the tumor periphery (original magnification, 200×) (c).
indexes of PMA and PA considerably overlap (6).
Molecular and Genetic Characteristics
The association of PA with NF1 has been recognized for many 
years, and PA constitutes one of the most common types of gliomas 
in patients with NF1. PMAs have also been reported in some 
patients with NF1 (26). The NF1 germline mutation is inherited 
in an autosomal dominant manner, but approximately half of all 
patients have a sporadic or de novo NF1 mutation (6). The NF1 
gene is located on chromosome 17q11.2 and encodes for the gene 
product neurofibromin, a GTPase-activating protein that functions 
as a negative regulator of the RAS protein in the mitogen MAPK 
pathway, which mediates cell growth, survival, and differentiation. 
The loss of the NF1 protein results in the activation of cell 
proliferation pathways and decreases cell differentiation through 
the activation of the MAPK pathway or alternatively through the 
activation of mammalian target of rapamycin (mTOR) pathway 
(6,49).
Information about the genetic and molecular characteristics 
of non-NF1-associated PA or PMA remained limited until 
approximately a decade ago when several independent studies 
found that the majority (>70%) of PA cases demonstrated the 
presence of an oncogenic tandem duplication at 7q34. This 
duplication results in a KIAA1549-BRAF fusion gene (Figure 
6) with constitutive BRAF kinase activity and MAPK pathway 
activation. KIAA1549-BRAF fusions are found at all anatomical 
locations but are more frequently found in cerebellar tumors 
than in other sites. Multiple differentexonic fusion combinations 
between KIAA1549 and BRAF have been reported but all result in 
the loss of the BRAF autoregulatory N-terminal domain and the 
retention of the BRAF kinase domain; these effects subsequently 
result in the constitutive activation of the oncogenic MAPK 
pathway (50-52). The frequency of KIAA1549-BRAF fusion is 
low in adult tumors (79% of tumors diagnosed in the first decade 
of life compared with 30% of patients aged 31-40 years and 7% of 
patients older than 40 years) (53). A small number of cases with 
other BRAF fusion gene partners have also been found, including 
FAM131B, RNF130, CLCN6, MKRN1, GNA11, QKI, FXR1, and 
MACF1 (6,54).
The abnormalities of genes encoding for proteins with influences 
on the MAPK pathway have been detected in almost all PAs and 
most PMAs (6).The second most common alteration is a BRAF 
hotspot mutation that results in a valine to glutamate substitution 
at position 600 (BRAF V600E mutation). This mutation has been 
found in approximately 10% of PA cases and frequently in PAs 
inextra-cerebellar locations, such as diencephalic tumors. This 
mutation is commonly found in other gliomas such as pleomorphic 
xanthoastrocytomas and gangliogliomas (55). Other alterations of 
the components of the MAPK pathway include FGFR1 mutation 
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FIG. 6. KIAA1549-BRAF fusion can be detected through fluorescence in situ hybridization. 
In this example, a yellow fusion signal is seen in most of the tumor nuclei.
FIG. 7. a-d. Capture-based next-generation sequencing findings for pilocytic astrocytoma: 
Genome-wide copy number profile revealing a focal copy number gain on chromosome 
7q34 that involves the BRAF gene without additional chromosomal gains, losses, or focal 
amplifications or deletions in a typical pilocytic astrocytoma (a). Final analysis confirming 
the presence of KIAA1549-BRAF gene fusion in the tumor (b). Example of an anaplastic 
pilocytic astrocytoma showing multiple chromosomal copy number changes, including 
the gain of 12q and the losses of 1p, 9p, and 13 (c). Anaplastic pilocytic astrocytoma 
demonstrating KIAA1549-BRAF gene fusion as well as an ATRX structural rearrangement 
and CDKN2A and CDKN2B deletions (d).
and fusions/duplication, NTRK2 fusions, SRGAP3-RAF1 fusion, 
KRAS mutation, and PTPN11 mutation (51,56,57). These MAPK 
pathway alterations appear to be largely mutually exclusive, 
with only rare reports of concurrent BRAF V600E mutation and 
KIAA1549-BRAF fusion (35,58).
The KIAA1549-BRAF fusion gene was initially thought to be 
highly specific for PAs, especially in tumors that virtually lack 
copy number variations or other mutations (Figure 7). However, 
rare examples of low-grade glioneuronal tumors, diffuse 
astrocytomas, oligodendrogliomas, and glioblastoma have been 
subsequently reported (50,59-62). Interestingly, while in some 
of these cases, the diagnoses are quite contentious and may be 
challenged, almost all tumors with the KIAA1549-BRAF fusion 
have histological components that appear to be typical for PA. For 
example, gangliogliomas in the posterior fossa (63) demonstrated 
two genetic subtypes, one of which had a typical PA component 
and the BRAF fusion. Recent studies on the gangliogliomas of the 
CNS also identified rare cases of gangliogliomas with a pilocytic 
component having the identical KIAA1549-BRAF fusion gene 
as those of PAs (Melike Pekmezci, personal communication). 
Nevertheless, the presence of KIAA1549-BRAF fusion and 
absence of other molecular genetic alterations remain consistent 
with the diagnosis of PA in the appropriate morphologic and 
clinical setting. 
Conflicting reports on the influence of KIAA1549-BRAF fusion on 
the behavior of PA or PMA exist. Several studies found that clinical 
outcome is independent of BRAF status (59,64,65), whereas others 
have found that fusion is an independent prognostic marker for 
significantly improved 5-year progression-free survival (58). 
One study has reported that disseminated PAs possess genetic 
features similar to those of classic PA, with a similar incidence of 
KIAA1549-BRAF fusions and BRAF mutations (66).
Approximately 60% of PMA cases harbor KIAA1549-BRAF 
fusions (58), whereas only the rare BRAF V600E mutation has 
been reported in these tumors (67). Gene expression microarray 
studies have shown differences in gene expression between PMA 
and PA, whereby PMAs overexpress the developmental genes H19 
and DACT2, extracellular matrix collagens (COL2A1; COL1A1), 
and IGF2BP3. However, how these genes influence the biological 
behavior of PMA remains unclear given that tumors with similar 
microarray profiles demonstrate diverse clinical outcomes (46).
Oncogene-induced senescence (OIS) refers to a process in tumors 
whereby the arrest of tumor growth is triggered in response to 
oncogene overexpression. In vitro studies have demonstrated 
that MAPK pathway activation using constitutively active BRAF 
induces the initial proliferation of PA cells, followed by OIS and the 
cessation of cellular proliferation (68,69). The induction of OIS by 
MAPK pathway activation due to solitary genetic alterations may 
be the underlying reason for the slow growth, indolent behavior, 
and/or spontaneous regression of PA. OIS may be mediated by 
the p16 protein (CDKN2A) given that in immortalized astrocytes, 
the loss of this protein abrogated OIS (69). Consistent with this 
hypothesis, patients with p16-negative tumors have significantly 
poorer outcomes than those without (68,70). Further more, the 
loss of p16 has been reported in some anaplastic PA (42,71), and 
a recent study involving 73 anaplastic astrocytomas with pilocytic 
features found that these gliomas are characterized by frequent 
MAPK pathway alterations, CDKN2A/B deletion, ATRX loss, 
and unfavorable prognosis (72). Notably, some treatments, such 
as radiotherapy, may abrogate OIS through the introduction of 
additional mutations or gene silencing within crucial checkpoints, 
such as CDKN2A and p53, and may then be associated with adverse 
outcomes (35).
Other genetic alterations that appear to adversely affect prognosis 
in PA include whole chromosome 7 gain and heterozygosity 
loss on 17p13, both of which are associated with an increased 
risk of recurrence (64,65). In addition, a recent meta-analysis of 
the H3K27M mutation in circumscribed (non-diffuse) gliomas 
included seven PAs with H3K27M mutation, these being associated 
with a poorer outcome than H3K27M wild-type circumscribed 
gliomas but better prognosis than diffuse gliomas with or without 
the mutation (73). The PI3K/AKT-mTOR pathway may also play 
a role in these tumors, with increased PI3K/AKT being reported 
in PA, particularly those with anaplasia (41,74). However, none of 
these studies provide conclusive evidence and convincing data that 
would constitute grounds to utilize these markers in the clinical 
diagnosis of PA or PMA.
Surgical resection is the preferred treatment for tumors at sites 
where gross total or subtotal resection can be achieved. However, 
adjuvant therapy may be required for patients with residual 
unresectable tumors or those with disease progression and/
or dissemination. The discovery of MAPK and mTOR pathway 
alterations have led to the use of novel targeted therapeutic 
agents. Multiple ongoing clinical trials use BRAF (ClinicalTrials.
gov: NCT01677741 and NCT01748149), MEK (ClinicalTrials.
gov: NCT01089101), and mTOR inhibitors (ClinicalTrials.gov: 
NCT01734512) as targeted agents for gliomas and other tumors 
that harbor mutations. These studies also use combinations of 
these drugs to circumvent cellular escape mechanisms and drug 
resistance, e.g. BRAF inhibitor daBRAFenib with MEK inhibitor 
trametinib (ClinicalTrials.gov: NCT02124772).
Caution should be exercised in the selection of these therapies 
given that our understanding of the complex molecular 
interactions that affect the MAPK pathway and its related 
pathways remains incomplete. This challenge was illustrated by 
an earlier experience with sorafenib, a multikinase inhibitor that 
targets BRAF, VEGFR, PDGFR, and c-kit. A multicenter phase 
II study conducted to determine the response rate to sorafenib 
in patients with recurrent or progressive pediatric low-grade 
gliomas (ClinicalTrials.gov: NCT01338857) was terminated early 
because of the unexpectedly rapid and high tumor progression 
rate. Subsequently, in vitro studies indicated that this effect is 
likely related to paradoxical ERK activation (75). Therapies 
should be as specific as possible to address the underlying 
molecular alterations within each tumor to minimize bystander 
effect. Comprehensive histological analysis and the identification 
of specific molecular/genetic abnormalities of the tumor and the 
interaction with the host should be critical in understanding the 
response and outcome of individual patients.
PA tumors have heterogeneous morphologies and behaviors. As 
a group, they show predominantly excellent prognosis. However, 
accurately predicting the behavior of individual PA tumors is 
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difficult given that tumors with similar histology and molecular 
genetic alterations behave differently. Our understanding of 
the biology of these tumors has greatly improved with recent 
molecular genetic discoveries, which have also led to new 
options for targeted therapy. However, the complex interactions 
that occur among altered pathways in these tumors remain to 
be fully elucidated. We hope that future research will provide a 
complete understanding of the drivers that initiate oncogenesis 
and that factors that lead to progression of these tumors to 
enable the development of effective therapies. Notably, PA and 
PMA are mostly indolent tumors and may exhibit a protracted 
clinical course and regression. Therefore, we recommend 
caution in treatment and avoid overtreatment, particularly in 
younger patients.
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